The Biostatistics and Bioinformatics Core for the M. D. Anderson Specialized Programs of Research Excellence in myeloma will serve multiple needs with respect to the planning and conduct of the SPORE research. This resource will be used for hypothesis refinement, experimental design, data management, quality control, and informative presentation of results, and will be available for all projects ofthe SPORE. From a biostatistical perspective, design and analysis of laboratory and clinical projects will be performed in collaboration with Dr. Donald A. Berry, Dr. Veerabhadran Baladandayuthapani, and Dr. Heather Y. Lin. Data from the SPORE clinical trials and laboratory projects will be entered into a custom database. Among other advantages, this computerized database will facilitate continuous monitoring of clinical trial results and will allow for automated data audits. Thus, from inception to reporting, translational experiments will benefit from the Biostatistics and Bioinformatics Core that will be used to augment existing M. D. Anderson biostatistics resources and to align these considerable resources with SPORE research objectives.
The Specific Aims of the Biostatistics and Bioinformatics Core are:
Specific Aim 1 : To provide the statistical design, sample size and power calculations for each project.
Specific Aim 2 : To facilitate prospective collecfion, entry, quality control, and integration of data for the basic science experiments and clinical trials arising form the ongoing research ofthe SPORE.
Specific Aim 3 : To provide innovative statistical modeling, simulation techniques, and data analyses needed by the projects and other Cores to achieve their Specific Aims.
Specific Aim 4 : To ensure that the results of all projects are based on well-designed experiments and are appropriately interpreted.

Public Health Relevance

The Biostatisfics and Bioinformatics Core will be used for hypothesis refinement, experimental design, data management, quality control, and informafive presentation of results, and will be available for all projects of the SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA142509-04
Application #
8543586
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2013-09-01
Budget End
2014-08-31
Support Year
4
Fiscal Year
2013
Total Cost
$90,589
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Jun; Medeiros, L Jeffrey; Young, Ken H (2018) Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma. Front Oncol 8:351
Ni, Haiwen; Shirazi, Fazal; Baladandayuthapani, Veerabhadran et al. (2018) Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191. Clin Cancer Res 24:6408-6420
Zhou, Liang; Zhang, Yu; Sampath, Deepak et al. (2018) Flavopiridol enhances ABT-199 sensitivity in unfavourable-risk multiple myeloma cells in vitro and in vivo. Br J Cancer 118:388-397
Davenport, Clemontina A; Maity, Arnab; Baladandayuthapani, Veerabhadran (2018) Functional interaction-based nonlinear models with application to multiplatform genomics data. Stat Med 37:2715-2733
Yao, Z; Deng, L; Xu-Monette, Z Y et al. (2018) Concordant bone marrow involvement of diffuse large B-cell lymphoma represents a distinct clinical and biological entity in the era of immunotherapy. Leukemia 32:353-363
Zhang, Xiaohui; Lee, Hans C; Shirazi, Fazal et al. (2018) Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myeloma. Leukemia 32:2224-2239
Thomas, Sheeba K; Cha, Soung-Chul; Smith, D Lynne et al. (2018) Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer 18:187
Xu-Monette, Zijun Y; Zhou, Jianfeng; Young, Ken H (2018) PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood 131:68-83
Zhang, Yu; Zhou, Liang; Leng, Yun et al. (2017) Positive transcription elongation factor b (P-TEFb) is a therapeutic target in human multiple myeloma. Oncotarget 8:59476-59491
Wang, Jinfen; Xu-Monette, Zijun Y; Jabbar, Kausar J et al. (2017) AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma. Am J Pathol 187:1700-1716

Showing the most recent 10 out of 203 publications